Thursday, September 21, 2017

ABIOMED RECEIVES FDA PMA APPROVAL FOR IMPELLA RP® FOR RIGHT HEART FAILURE

DANVERS, Mass., Sept 21 (Bernama-GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed’s platform of PMA approved devices.

With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication:

http://mrem.bernama.com/viewsm.php?idm=30106

No comments:

Post a Comment